spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  TRANSDUR 

 HSMN NewsFeed - 30 Jul 2026
CereVasc Opens New Massachusetts Facility in Preparation for eShunt(R) System Commercialization
Devices Neurosurgery
 HSMN NewsFeed - 23 Jun 2026
CereVasc, Inc. Completes Enrollment in STRIDE Pivotal Trial of the eShunt(R) System
Devices Neurosurgery
 HSMN NewsFeed - 4 Jun 2026
CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt(R) System for the Treatment of Normal Pressure Hydrocephalus
Devices Interventional Neurosurgery Venture Capital
 HSMN NewsFeed - 4 Mar 2026
First-in-Human Use of CereVasc(R) eShunt(R) System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical Outcomes
Devices Neurosurgery
 HSMN NewsFeed - 16 Jul 2024
CereVasc Announces Appointments of New Directors
Devices Neurosurgery Personnel
 HSMN NewsFeed - 13 May 2024
CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt(R) System for the Treatment of Normal Pressure Hydrocephalus
Devices Neurosurgery Venture Capital
 HSMN NewsFeed - 7 Jan 2014
Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR(R) Pain Patch
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 22 Oct 2013
Pfizer Proceeding with REMOXY(R) Development
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 27 Sep 2013
DURECT Announces Changes to its Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 20 Jun 2013
DURECT Announces FDA Acceptance of New Drug Application (NDA) Submission for POSIDUR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 19 Jan 2010
DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2009
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Biopharmaceuticals
 HSMN NewsFeed - 22 Sep 2008
Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain Patch
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 7 Apr 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 3 Jan 2007
DURECT Starts Phase II Dosing for TRANSDUR(TM)-Bupivacaine (DUR-843)
Biopharmaceuticals Drug Delivery
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
TRANSDUR
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!